Curanex Pharmaceuticals Enters Material Definitive Agreement
Ticker: CURX · Form: 8-K · Filed: Aug 26, 2025 · CIK: 2025942
| Field | Detail |
|---|---|
| Company | Curanex Pharmaceuticals Inc (CURX) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $4.00, $15,000,000, $12,114,369 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Curanex Pharma (CRNX) signed a big deal, filing an 8-K on 8/25/25. Details TBD.
AI Summary
Curanex Pharmaceuticals Inc. announced on August 25, 2025, that it has entered into a material definitive agreement. The company, incorporated in Nevada with its principal executive offices in Jericho, NY, filed a Form 8-K to report this event. Specific details of the agreement, including the counterparty and financial terms, are not provided in this excerpt.
Why It Matters
This filing indicates a significant business development for Curanex Pharmaceuticals, potentially impacting its future operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material event, but the lack of specific details about the agreement introduces uncertainty.
Key Players & Entities
- Curanex Pharmaceuticals Inc (company) — Registrant
- August 25, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Jericho, NY (location) — Principal executive offices
- 2 Jericho Plaza, Suite 101B (address) — Business address
FAQ
What is the nature of the material definitive agreement entered into by Curanex Pharmaceuticals?
The provided excerpt does not specify the nature of the material definitive agreement.
Who is the other party to the material definitive agreement?
The identity of the other party to the agreement is not disclosed in this filing excerpt.
What is the effective date of the material definitive agreement?
The earliest event reported is August 25, 2025, which is the date of the report and likely the effective date or announcement date of the agreement.
What is Curanex Pharmaceuticals' principal executive office address?
Curanex Pharmaceuticals' principal executive office is located at 2 Jericho Plaza, Suite 101B, Jericho, NY 11753.
What is Curanex Pharmaceuticals' SIC code?
Curanex Pharmaceuticals' Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 836 words · 3 min read · ~3 pages · Grade level 13.8 · Accepted 2025-08-26 07:30:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CURX The Nasdaq Capital M
- $4.00 — Stock"), at a public offering price of $4.00 per share, for gross Offering proceeds
- $15,000,000 — r share, for gross Offering proceeds of $15,000,000. The Company has also granted the under
- $12,114,369 — enses, are expected to be approximately $12,114,369. The Company anticipates using the net
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex1-1.htm (EX-1.1) — 344KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001493152-25-012316.txt ( ) — 657KB
- curx-20250825.xsd (EX-101.SCH) — 3KB
- curx-20250825_lab.xml (EX-101.LAB) — 33KB
- curx-20250825_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Curanex Pharmaceuticals Inc Date: August 26, 2025 By: /s/ Jun Liu Name: Jun Liu Title: Chief Executive Officer